F-18 Amyloid Beta Ligand Purification via Ethanol HPLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing F-18 labeled fluoropegylated (aryl/heteroaryl vinyl)-phenyl methyl amines face challenges in achieving high chemical and radiochemical purities, particularly at higher radioactivity levels, and require complex processes that are not suitable for large-scale production or distribution without radiopharmaceutical facilities, with radiolysis being a significant issue.
Innovation Solution
A modified HPLC purification process using an ethanol/buffer mixture instead of acetonitrile/buffer, allowing direct transfer of the product fraction into an injectable formulation, reducing the complexity and time of the manufacturing process while maintaining high radiochemical purity (>95%) even at higher activity levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If acetonitrile/buffer solvent system is used for HPLC purification, then high chemical and radiochemical purities can be achieved, but the process complexity increases and requires extensive re-formulation steps
Solution Approach 1:
The patent changes the solvent system parameters from acetonitrile/buffer to ethanol/water buffer mixture. This parameter change allows the HPLC purification to produce a product that is directly suitable for injection, eliminating the need for complex re-formulation steps while maintaining high radiochemical purity (>95%). The ethanol-based solvent system is the key parameter modification that resolves the contradiction between purity and process complexity.
2Manufacturing precision
If conventional HPLC purification with acetonitrile is used, then product purity is maintained, but additional re-formulation steps are required for injectable formulation
Solution Approach 1:
The patent merges the HPLC purification step with the formulation step by using an ethanol/water buffer solvent system that is compatible with both purification and final injectable formulation requirements. This consolidation eliminates the separate re-formulation step, reducing manufacturing time while maintaining high chemical and radiochemical purities. The single solvent system serves dual purposes: purification and formulation.
3Quantity of substance
If higher radioactivity levels are produced, then more diagnostic material is available for distribution, but radiochemical purity decreases due to radiolysis
Solution Approach 1:
The patent changes the HPLC solvent from acetonitrile-based to ethanol-based system, which is less prone to radiolysis. This parameter change enables the production of higher radioactivity levels (up to 100 GBq) while maintaining high radiochemical purity (>95%). The ethanol solvent system is more radiolytically stable, allowing higher quantities to be produced without the purity degradation that occurs with conventional solvent systems.
4Manufacturing precision
If complex purification processes are used, then high purity products are obtained, but the process is not suitable for large-scale production or distribution without radiopharmaceutical facilities
Solution Approach 1:
The patent modifies the HPLC solvent composition to ethanol/water buffer, which simplifies the overall manufacturing process. This parameter change makes the process suitable for large-scale production and distribution without requiring specialized radiopharmaceutical facilities, while still achieving high product purity. The ethanol-based system is more compatible with standard pharmaceutical manufacturing infrastructure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new method ensures high radiochemical purity and simplifies the production process, enabling the production of higher activity levels (up to 100 GBq) with reduced variability and complexity, making it suitable for widespread use and distribution without the need for extensive re-formulation or radiopharmaceutical facilities.
Implementation Method 1
Purification and Formulation of compound of Formula I by HPLC using a solvent system that can be part of an injectable Formulation
Implementation Method 2
Radiofluorination of compound of Formula II with a F-18 fluorinating agent, to obtain compound of Formula I
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention relates to methods, which provide access to [F-18]fluoropegylated (aryl/heteroaryl vinyl)-phenyl methyl amine derivatives.